Drugging the ‘undruggable’ cancer targets

Cancer Genome Landscapes

Vogelstein, B., Papadopoulos, N., Velculescu, V. E., Zhou, S., Diaz, L. A., & Kinzler, K. W. (2013) · Science · doi:10.1126/science.1235122 · Cited by 7,863

The future of immune checkpoint therapy

Sharma, P., & Allison, J. P. (2015) · Science · doi:10.1126/science.aaa8172 · Cited by 4,878

Selective inhibition of BET bromodomains

Filippakopoulos, P., Qi, J., Picaud, S., Shen, Y., Smith, W. B., Fedorov, O., Morse, E. M., Keates, T., Hickman, T. T., Felletar, I., et al. (2010) · Nature · doi:10.1038/nature09504 · Cited by 4,262

MYC on the Path to Cancer

Dang, C. V. (2012) · Cell · doi:10.1016/j.cell.2012.03.003 · Cited by 3,390

Peptide therapeutics: current status and future directions

Fosgerau, K., & Hoffmann, T. (2014) · Drug Discovery Today · doi:10.1016/j.drudis.2014.10.003 · Cited by 3,160

AR-V7 and Resistance to Enzalutamide and Abiraterone in Prostate Cancer

Antonarakis, E. S., Lu, C., Wang, H., Luber, B., Nakazawa, M., Roeser, J. C., Chen, Y., Mohammad, T. A., Chen, Y., Fedor, H. L., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1315815 · Cited by 2,710

K-Ras(G12C) inhibitors allosterically control GTP affinity and effector interactions

Ostrem, J. M., Peters, U., Sos, M. L., Wells, J. A., & Shokat, K. M. (2013) · Nature · doi:10.1038/nature12796 · Cited by 2,557

Drugging the undruggable RAS: Mission Possible?

Cox, A. D., Fesik, S. W., Kimmelman, A. C., Luo, J., & Der, C. J. (2014) · Nature Reviews Drug Discovery · doi:10.1038/nrd4389 · Cited by 1,997

Macropinocytosis of protein is an amino acid supply route in Ras-transformed cells

Commisso, C., Davidson, S. M., Soydaner-Azeloglu, R. G., Parker, S. J., Kamphorst, J. J., Hackett, S., Grabocka, E., Nofal, M., Drebin, J. A., Thompson, C. B., et al. (2013) · Nature · doi:10.1038/nature12138 · Cited by 1,683

Emerging mechanisms of resistance to androgen receptor inhibitors in prostate cancer

Watson, P. A., Arora, V. K., & Sawyers, C. L. (2015) · Nature Reviews Cancer · doi:10.1038/nrc4016 · Cited by 1,536

Divarasib in the Evolving Landscape of KRAS G12C Inhibitors for NSCLC

Brazel, D., & Nagasaka, M. (2024) · Targeted Oncology · doi:10.1007/s11523-024-01055-y · Cited by 21

Drug-Free Mesoporous Silica Nanoparticles Enable Suppression of Cancer Metastasis and Confer Survival Advantages to Mice with Tumor Xenografts

Lee, Y.-T., Wu, S., Wu, C. ‐., Lin, Y.-H., Lin, C.-K., Chen, Z.-A., Sun, T.-C., Chen, Y., Chen, P., Mou, C., et al. (2024) · ACS Applied Materials & Interfaces · doi:10.1021/acsami.4c16609 · Cited by 20

Calmodulin and IQGAP1 activation of PI3Kα and Akt in KRAS, HRAS and NRAS-driven cancers

Nussinov, R., Zhang, M., Tsai, C., & Jang, H. (2017) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2017.10.032 · Cited by 21

Conformational editing of intrinsically disordered protein by α-methylation

Bauer, V., Schmidtgall, B., Gógl, G., Dolenc, J., Ősz, J., Nominé, Y., Kostmann, C., Cousido-Siah, A., Mitschler, A., Rochel, N., et al. (2020) · Chemical Science · doi:10.1039/d0sc04482b · Cited by 20

Targeting lipid metabolism in cancer: neuroblastoma

Agostini, M., Melino, G., Habeb, B. F., Calandria, J. M., & Bazan, N. G. (2022) · Cancer and Metastasis Reviews · doi:10.1007/s10555-022-10040-8 · Cited by 20

Metabolism-based targeting of MYC via MPC-SOD2 axis-mediated oxidation promotes cellular differentiation in group 3 medulloblastoma

Martell, E., Kuzmychova, H., Kaul, E., Senthil, H., Chowdhury, S. R., Morrison, L. C., Fresnoza, A. L., Zagozewski, J. L., Venugopal, C., Anderson, C. M., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-38049-9 · Cited by 20

Discovery and Structure-Based Design of Inhibitors of the WD Repeat-Containing Protein 5 (WDR5)–MYC Interaction

Ding, J. H., Liu, L., Chiang, Y., Zhao, M., Liu, H., Yang, F., Shen, L., Lin, Y. L., Deng, H., Gao, J., et al. (2023) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.3c00787 · Cited by 19

Recent advances in the molecular design and applications of proteolysis targeting chimera-based multi-specific antiviral modality

Zhou, Y., Xu, S., López‐Carrobles, N., Ding, D., Liu, X., Menéndez‐Arias, L., & Zhan, P. (2023) · Acta Materia Medica · doi:10.15212/amm-2023-0019 · Cited by 20

Role of HOX genes in cancer progression and their therapeutical aspects.

Yadav, C., Yadav, R., Nanda, S., Ranga, S., Ahuja, P., & Tanwar, M. (2024) · Gene · doi:10.1016/j.gene.2024.148501 · Cited by 17

A patent review of RAF kinase inhibitors (2010–2018)

Man, R., Zhang, Y., Jiang, A.-Q., & Zhu, H. (2019) · Expert Opinion on Therapeutic Patents · doi:10.1080/13543776.2019.1651842 · Cited by 19

The Road Not Taken with Pyrrole-Imidazole Polyamides: Off-Target Effects and Genomic Binding

Lin, J. C., & Nagase, H. (2020) · Biomolecules · doi:10.3390/biom10040544 · Cited by 19

Peptide/Lipid-Associated Nucleic Acids (PLANAs) as a Multicomponent siRNA Delivery System

Hall, R., Alasmari, A., Mozaffari, S., Mahdipoor, P., Parang, K., & Aliabadi, H. M. (2021) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.0c00969 · Cited by 20

Synergistic Interplay of Covalent and Non‐Covalent Interactions in Reactive Polymer Nanoassembly Facilitates Intracellular Delivery of Antibodies

Dutta, K., Kanjilal, P., Das, R., & Thayumanavan, S. (2020) · Angewandte Chemie · doi:10.1002/ange.202010412 · Cited by 18

De Novo Design of Peptide Binders to Conformationally Diverse Targets with Contrastive Language ModelingPreprint

Bhat, S. M., Palepu, K., Hong, L., Mao, J., Ye, T., Iyer, R., Zhao, L., Chen, T., Vincoff, S., Watson, R., et al. (2024) · bioRxiv · doi:10.1101/2023.06.26.546591 · Cited by 90

Allostery in Disease: Anticancer Drugs, Pockets, and the Tumor Heterogeneity Challenge

Nussinov, R., Yavuz, B. R., & Jang, H. (2025) · Journal of Molecular Biology · doi:10.1016/j.jmb.2025.169050 · Cited by 19

Targeting the ERK mitogen-activated protein kinase cascade for the treatment of KRAS-mutant pancreatic cancer

Diehl, J. N., Hibshman, P. S., Ozkan‐Dagliyan, I., Goodwin, C. M., Howard, S. V., Cox, A. D., & Der, C. J. (2022) · Advances in cancer research · doi:10.1016/bs.acr.2021.07.008 · Cited by 18

Clinical sequencing identifies potential actionable alterations in a high rate of urachal and primary bladder adenocarcinomas

Váradi, M., Nagy, N. T., Reis, H., Hadaschik, B. A., Niedworok, C., Módos, O., Szendrői, A., Ablat, J., Black, P. C., Keresztes, D., et al. (2023) · Cancer Medicine · doi:10.1002/cam4.5639 · Cited by 18

Chemical Proteomics–Guided Discovery of Covalent Ligands for Cancer Proteins

Zhang, X., & Cravatt, B. F. (2024) · Annual Review of Cancer Biology · doi:10.1146/annurev-cancerbio-061421-041946 · Cited by 19

Augmentation of Myc-Dependent Mitotic Gene Expression by the Pygopus2 Chromatin Effector

Andrews, P., Popadiuk, C., Belbin, T. J., & Kao, K. R. (2018) · Cell Reports · doi:10.1016/j.celrep.2018.04.020 · Cited by 18

Strategies towards Targeting Gαi/s Proteins: Scanning of Protein‐Protein Interaction Sites To Overcome Inaccessibility

Nubbemeyer, B., Pepanian, A., George, A. A. P., & Imhof, D. (2021) · ChemMedChem · doi:10.1002/cmdc.202100039 · Cited by 18

Expanding the Repertoire for “Large Small Molecules”: Prodrug ABBV-167 Efficiently Converts to Venetoclax with Reduced Food Effect in Healthy Volunteers

Salem, A. H., Tao, Z., Bueno, O. F., Chen, J., Chen, S., Edalji, R. P., Elmore, S. W., Fournier, K. M., Harper, K. C., Hong, R. S., et al. (2021) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-21-0077 · Cited by 18

Single-molecule analysis of interaction between p53TAD and MDM2 using aerolysin nanopores

Oh, S., Lee, M., & Chi, S. (2021) · Chemical Science · doi:10.1039/d1sc00386k · Cited by 19

Enhancement of Gene Knockdown on CD22-Expressing Cells by Chemically Modified Glycan Ligand–siRNA Conjugates

Harumoto, T., Iwai, H., Tanigawa, M., Kubo, T., Atsumi, T., Tsutsumi, K., Takashima, M., Destito, G., Soloff, R. S., Tomizuka, K., et al. (2022) · ACS Chemical Biology · doi:10.1021/acschembio.1c00652 · Cited by 18

Current Drug Discovery

Hale, J. J. (2022) · Wiley eBooks · doi:10.1002/9781119627784.ch1 · Cited by 18

A comprehensive mechanistic investigation of factors affecting intestinal absorption and bioavailability of two PROTACs in rats

Niessen, J., Arendt, N., Sjöblom, M., Dubbelboer, I. R., Borchardt, T. B., Koziolek, M., Hedeland, M., Lennernäs, H., Indulkar, A. S., & Dahlgren, D. (2025) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/j.ejpb.2025.114719 · Cited by 18

Diffusion Limit and the Reactivity/Affinity Conundrum: Implications for Optimization and Hit Finding for Irreversible Modulators

Srinivasan, B. (2025) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.4c02863 · Cited by 19

A CRAF/glutathione-S-transferase P1 complex sustains autocrine growth of cancers with KRAS and BRAF mutations

Niitsu, Y., Sato, Y., Takanashi, K., Hayashi, T., Kubo-Birukawa, N., Shimizu, F., Fujitani, N., Shimoyama, R., Kukitsu, T., Kurata, W., et al. (2020) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2000361117 · Cited by 16

PLZF and its fusion proteins are pomalidomide-dependent CRBN neosubstrates

Shimizu, N., Asatsuma‐Okumura, T., Yamamoto, J., Yamaguchi, Y., Handa, H., & Ito, T. (2021) · Communications Biology · doi:10.1038/s42003-021-02801-y · Cited by 17

BET inhibition is an effective approach against KRAS-driven PDAC and NSCLC

Jauset, T., Massó-Vallés, D., Martínez-Martín, S., Beaulieu, M.-È., Foradada, L., Fiorentino, F. P., Yokota, J., Haendler, B., Siegel, S., Whitfield, J. R., et al. (2018) · Oncotarget · doi:10.18632/oncotarget.24648 · Cited by 19

Computational models of melanoma

Albrecht, M., Lucarelli, P., Kulms, D., & Sauter, T. (2020) · Theoretical Biology and Medical Modelling · doi:10.1186/s12976-020-00126-7 · Cited by 17

A guide for bioinformaticians: ‘omics-based drug discovery for precision oncology

Mun, J., Choi, G., & Lim, B. (2020) · Drug Discovery Today · doi:10.1016/j.drudis.2020.08.004 · Cited by 18

Affinity Enhancement of Protein Ligands by Reversible Covalent Modification of Neighboring Lysine Residues

Corso, A. D., Catalano, M., Schmid, A. S., Scheuermann, J., & Neri, D. (2018) · Angewandte Chemie · doi:10.1002/ange.201811650 · Cited by 19

Photolysis-generated sulfenylnitrenes enable site-selective nitrogen-atom insertion into N-heterocycles

Kafle, P., Kharel, P., Nilson, D., Herndon, D., Yasuda, S., & Sharma, I. (2025) · Chem · doi:10.1016/j.chempr.2025.102753 · Cited by 18

Comparative reactivity profiling of cysteine-specific probes by chemoproteomics

Yang, F., Chen, N., Wang, F., Jia, G., & Wang, C. (2022) · Current Research in Chemical Biology · doi:10.1016/j.crchbi.2022.100024 · Cited by 16

Intrinsic suppression of type I interferon production underlies the therapeutic efficacy of IL-15-producing natural killer cells in B-cell acute lymphoblastic leukemia

Kumar, A., Khani, A. T., Duault, C., Aramburo, S., Ortiz, A. S., Lee, S. J., Chan, A., McDonald, T., Huang, M., Lacayo, N. J., et al. (2023) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2022-006649 · Cited by 16

Leveraging intracellular ALDH1A1 activity for selective cancer stem-like cell labeling and targeted treatment via in vivo click reaction

Yang, B., Zhou, J., Cai, K., Wang, Y., Feng, Y., Li, W., Jiang, Y., Kuo, S. H., Roy, J., Anorma, C., et al. (2023) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2302342120 · Cited by 16

E3MPH16: An efficient endosomolytic peptide for intracellular protein delivery

Kawaguchi, Y., Kawamura, Y., Hirose, H., Kiyokawa, M., Hirate, M., Hirata, T., Higuchi, Y., & Futaki, S. (2024) · Journal of Controlled Release · doi:10.1016/j.jconrel.2024.01.067 · Cited by 16

Insights into the Links between MYC and 3D Chromatin Structure and Epigenetics Regulation: Implications for Cancer Therapy

Amjadi‐Moheb, F., Paniri, A., & Akhavan‐Niaki, H. (2021) · Cancer Research · doi:10.1158/0008-5472.can-20-3613 · Cited by 16

Rationale for MYC imaging and targeting in pancreatic cancer

Schneider, G., Wirth, M., Keller, U. B., & Saur, D. (2021) · EJNMMI Research · doi:10.1186/s13550-021-00843-1 · Cited by 15

D154Q Mutation does not Alter KRAS Dimerization

Grozavu, I., Stuart, S. E., Lyakisheva, A., Yao, Z., Pathmanathan, S., Ohh, M., & Štagljar, I. (2021) · Journal of Molecular Biology · doi:10.1016/j.jmb.2021.167392 · Cited by 16

Activation of Rho Family GTPases by Small Molecules

Palsuledesai, C. C., Surviladze, Z., Waller, A., Miscioscia, T. F., Guo, Y., Wu, Y., Strouse, J., Romero, E., Salas, V. M., Curpan, R. F., et al. (2018) · ACS Chemical Biology · doi:10.1021/acschembio.8b00038 · Cited by 18

Verteporfin-induced proteotoxicity impairs cell homeostasis and survival in neuroblastoma subtypes independent of YAP/TAZ expression

Condurat, A.-L., Aminzadeh-Gohari, S., Malnar, M., Schider, N., Opitz, L., Thomas, R., Menon, V., Kofler, B., & Pruszak, J. (2023) · Scientific Reports · doi:10.1038/s41598-023-29796-2 · Cited by 14

c-Myc promotes metabolic reprogramming in pulmonary hypertension via the stimulation of glutaminolysis and the reductive tricarboxylic acid cycle

Yegambaram, M., Sun, X., Lü, Q., Flores, A. G., Zemskova, M., Soto, J. E., Rauckhorst, A. J., Maltepe, E., Wang, T., Fineman, J. R., et al. (2025) · Redox Biology · doi:10.1016/j.redox.2025.103765 · Cited by 17

Druglike Molecular Degraders of the Oncogenic RNA-Binding Protein HuR

Kassabri, L., & Benhamou, R. I. (2025) · JACS Au · doi:10.1021/jacsau.5c00551 · Cited by 16

Dual Targeting Oncoproteins MYC and HIF1α Regresses Tumor Growth of Lung Cancer and Lymphoma

Huang, X., Liu, Y., Wang, Y., Bailey, C., Zheng, P., & Liu, Y. (2021) · Cancers · doi:10.3390/cancers13040694 · Cited by 17

Ras superfamily GTPase activating proteins in cancer: Potential therapeutic targets?

Xiao, H., Wang, G., Zhao, M., Wen, S., Ouyang, L., & Sun, Q. (2023) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2023.115104 · Cited by 18

Elevated nuclear PIGL disrupts the cMyc/BRD4 axis and improves PD-1 blockade therapy by dampening tumor immune evasion

Yu, H. T., Shi, T., Yao, L., Xu, D., Ding, Y., Xia, Q., Liu, W., & Wang, X. (2023) · Cellular and Molecular Immunology · doi:10.1038/s41423-023-01048-3 · Cited by 15

Coinhibition of topoisomerase 1 and BRD4-mediated pause release selectively kills pancreatic cancer via readthrough transcription

Cameron, D. P., Grosser, J., Ladigan, S., Kuzin, V., Iliopoulou, E., Wiegard, A., Benredjem, H., Jackson, K., Liffers, S. T., Lueong, S., et al. (2023) · Science Advances · doi:10.1126/sciadv.adg5109 · Cited by 16

Nucleic acid therapeutics as differentiation agents for myeloid leukemias

Kovecses, O., Mercier, F., & McKeague, M. (2024) · Leukemia · doi:10.1038/s41375-024-02191-0 · Cited by 18

Comprehensive review on leucine-rich pentatricopeptide repeat-containing protein (LRPPRC, PPR protein): A burgeoning target for cancer therapy

Ge, Y., Janson, V., & Liu, H. (2024) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2024.136820 · Cited by 17

DCTPP1: A promising target in cancer therapy and prognosis through nucleotide metabolism

Liu, S., Li, F., & Wang, Z. (2025) · Drug Discovery Today · doi:10.1016/j.drudis.2025.104348 · Cited by 18

Non-coding RNAs, metabolic stress and adaptive mechanisms in cancer

Liu, X., Feng, S., Zhang, X. D., Li, J., Zhang, K., Wu, M., & Thorne, R. F. (2020) · Cancer Letters · doi:10.1016/j.canlet.2020.06.024 · Cited by 15

RRx-001, a downregulator of the CD47- SIRPα checkpoint pathway, does not cause anemia or thrombocytopenia

Oronsky, B. T., Cabrales, P., Caroen, S. Z., Guo, X., Scribner, C. L., Oronsky, A. L., & Reid, T. R. (2021) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1080/17425255.2021.1876025 · Cited by 15

Cytosolic Delivery of Small Protein Scaffolds Enables Efficient Inhibition of Ras and Myc

Chan, A., Wang, H. H., Haley, R. M., Song, C., Gonzalez-Martinez, D., Bugaj, L. J., Mitchell, M. J., & Tsourkas, A. (2022) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.1c00798 · Cited by 15

Targeting Mutant Kirsten Rat Sarcoma Viral Oncogene Homolog in Non-Small Cell Lung Cancer: Current Difficulties, Integrative Treatments and Future Perspectives

Li, J., Li, R., Ma, L.-R., Wang, P., Xu, D., Huang, J., Li, L.-Q., Tang, L. L., Xie, Y., Leung, E. L., et al. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.875330 · Cited by 17

Structure‐based discovery of Licoflavone B and Ginkgetin targeting c‐Myc G‐quadruplex to suppress c‐Myc transcription and myeloma growth

Liu, L., Geng, X., Zhang, J., Li, S., & Gao, J. (2022) · Chemical Biology & Drug Design · doi:10.1111/cbdd.14064 · Cited by 15

Whole-exome sequencing analysis of NSCLC reveals the pathogenic missense variants from cancer-associated genes

Kumar, S. U., Balasundaram, A., Hephzibah Cathryn, R., Varghese, R. P., Ramamoorthy, S., Ramanathan, G., Younes, S. N., Zayed, H., & Doss, C. G. P. (2022) · Computers in Biology and Medicine · doi:10.1016/j.compbiomed.2022.105701 · Cited by 15

A Raman/fluorescence dual-modal imaging guided synergistic photothermal and photodynamic therapy nanoplatform for precision cancer theranostics

Fu, L., Huang, Y. L., Hou, J., Sun, M., Wang, L., Wang, X., & Chen, L. (2022) · Journal of Materials Chemistry B · doi:10.1039/d2tb01696f · Cited by 16

Medicinal Chemistry Strategies for the Development of Inhibitors Disrupting β-Catenin’s Interactions with Its Nuclear Partners

Zhang, H., Liu, C., Zhu, D., Zhang, Q., & Li, J. (2022) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.2c01016 · Cited by 15

Aptamers and apple pies: a mini-review of PSMA aptamers and lessons from Donald S. Coffey.

Lupold, S. E. (2018) · Europe PMC (PubMed Central) · Cited by 15

Pan-cancer integrated bioinformatic analysis of RNA polymerase subunits reveal RNA Pol I member CD3EAP regulates cell growth by modulating autophagy

Bhandari, N., Acharya, D., Chatterjee, A., Mandve, L., Kumar, P., Pratap, S., Malakar, P., & Shukla, S. K. (2023) · Cell Cycle · doi:10.1080/15384101.2023.2265676 · Cited by 14

Obesity under the moonlight of c-MYC

Nevzorova, Y. A., & Cubero, F. J. (2023) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2023.1293218 · Cited by 16

Targeted-Neuroinflammation Mitigation Using Inflammasome-Inhibiting Nanoligomers is Therapeutic in an Experimental Autoimmune Encephalomyelitis Mouse Model

Sharma, S., Risen, S. J., Gilberto, V. S., Boland, S. W., Chatterjee, A., Moreno, J. A., & Nagpal, P. (2024) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.4c00024 · Cited by 13

Molecular properties, including chameleonicity, as essential tools for designing the next generation of oral beyond rule of five drugs

Caron, G., Jiménez, D. G., Vallaro, M., Vitagliano, L., Lopez, L. L., Apprato, G., & Ermondi, G. (2024) · ADMET & DMPK · doi:10.5599/admet.2334 · Cited by 15

Reciprocal Induction of MDM2 and MYCN in Neural and Neuroendocrine Cancers

Tran, H. N., Singh, H. P., Guo, W., Cambier, L., Riggan, L., Shackleford, G. M., Thornton, M. E., Grubbs, B. H., Erdreich‐Epstein, A., Qi, D.-L., et al. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.563156 · Cited by 14

A Long Overdue Targeted Treatment for KRAS Mutations in NSCLC: Spotlight on Adagrasib

Brazel, D., Arter, Z., & Nagasaka, M. (2022) · Lung Cancer Targets and Therapy · doi:10.2147/lctt.s383662 · Cited by 16

Sialylated IgG-activated integrin β4-Src-Erk axis stabilizes c-Myc in a p300 lysine acetyltransferase-dependent manner to promote colorectal cancer liver metastasis

Chen, J., Zhang, S., Huang, X., Wang, Q., Xu, W., Huang, J., Su, Y., Sun, Q., Du, X., Xing, B., et al. (2025) · Neoplasia · doi:10.1016/j.neo.2025.101140 · Cited by 15

Programmable PROTAC delivery for precise and spatiotemporal protein degradation

Sheng, J., Ma, T., Wu, Y., & Wang, M. (2026) · Chemical Communications · doi:10.1039/d5cc05651a · Cited by 13

Targeted Protein Degradation: An Important Tool for Drug Discovery for “Undruggable” Tumor Transcription Factors

Dai, M., Sridhar, R., Li, R., Tan, R., Yan, K., Fan, G., & Liu, M. (2022) · Technology in Cancer Research & Treatment · doi:10.1177/15330338221095950 · Cited by 14

Splice‐switch oligonucleotide‐based combinatorial platform prioritizes synthetic lethal targets CHK1 and BRD4 against MYC ‐driven hepatocellular carcinoma

Thng, D. K. H., Toh, T. B., Pigini, P., Hooi, L., Dan, Y. Y., Chow, P. K. H., Bonney, G. K., Rashid, M. B. M. A., Guccione, E., Wee, D. K. B., et al. (2022) · Bioengineering & Translational Medicine · doi:10.1002/btm2.10363 · Cited by 13

Dual inhibition of atypical PKC signaling and PI3K/Akt signaling dysregulates c-Myc to induce apoptosis in clear cell Renal Cell Carcinoma

Khalid, K. M., Ratnayake, W. S., Apostolatos, C., & Acevedo-Duncan, M. E. (2024) · Frontiers in Oncology · doi:10.3389/fonc.2023.1213715 · Cited by 12

A novel combined therapeutic strategy of Nano-EN-IR@Lip mediated photothermal therapy and stem cell inhibition for gastric cancer

Yang, L., Du, Y.-E., Liao, F., Huang, T., Liu, Y., Liu, J., Wang, C., Zhan, Z., Cao, Y., Wang, Z., et al. (2024) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2024.116486 · Cited by 13

Breaking barriers: Innovative approaches for skin delivery of RNA therapeutics

Subramanian, G., Kalidasan, K., Quah, S., Qi Chou, G. H., Chan, J., Wacker, M. G., & Sampath, P. (2024) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2024.124435 · Cited by 13

Directly Suppressing MYC Function with Novel Alkynyl-Substituted Phenylpyrazole Derivatives that Induce Protein Degradation and Perturb MYC/MAX Interaction

Zhao, C., Zhao, F., Yang, L., Wang, Y., Wang, H., Fang, F., Zuo, H., Li, Z., He, G., Zhan, W., et al. (2024) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.4c00272 · Cited by 13

Utilizing aptamers in targeted protein degradation strategies for disease therapy

Li, L., Xie, S., Zhou, J., & Ran, J. (2025) · The Journal of Pathology · doi:10.1002/path.6422 · Cited by 13

TGFβ promotes YAP‐dependent AXL induction in mesenchymal‐type lung cancer cells

Choi, J., Lee, H., Kwon, E., Kong, H., Kwon, O., & Cha, H. (2020) · Molecular Oncology · doi:10.1002/1878-0261.12857 · Cited by 13

Ppp6c deficiency accelerates K‐rasG12D‐induced tongue carcinogenesis

Kishimoto, K., Kanazawa, K., Nomura, M., Tanaka, T., Shigemoto-Kuroda, T., Fukui, K., Miura, K., Kurosawa, K., Kawai, M., Kato, H., et al. (2021) · Cancer Medicine · doi:10.1002/cam4.3962 · Cited by 13

Targeting Gαi/s Proteins with Peptidyl Nucleotide Exchange Modulators

Nubbemeyer, B., George, A. A. P., Kühl, T., Pepanian, A., Beck, M. S., Maghraby, R., Boushehri, M. A. S., Muehlhaupt, M., Pfeil, E. M., Annala, S., et al. (2022) · ACS Chemical Biology · doi:10.1021/acschembio.1c00929 · Cited by 13

Applications and Limitations of Oxime‐Linked “Split PROTACs”

Gui, W., & Kodadek, T. J. (2022) · ChemBioChem · doi:10.1002/cbic.202200275 · Cited by 14

Construction of a synthetic methodology-based library and its application in identifying a GIT/PIX protein–protein interaction inhibitor

Gu, J., Peng, R.-K., Guo, C., Zhang, M., Yang, J., Yan, X. H., Zhou, Q., Li, H., Wang, N., Zhu, J., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-34598-7 · Cited by 15

Prospects of Using Protein Engineering for Selective Drug Delivery into a Specific Compartment of Target Cells

Rosenkranz, A. A., & Slastnikova, T. A. (2023) · Pharmaceutics · doi:10.3390/pharmaceutics15030987 · Cited by 14

BOOMER

Song, Y., Chua, H. E., Bhowmick, S. S., Choi, B. K. K., & Zhou, S. (2018) · ACM SIGMOD International Conference on Management of Data (SIGMOD) · doi:10.1145/3183713.3196902 · Cited by 13

Drug Design of “Undruggable” Targets

Wang, J., Li, S., & Li, H. (2019) · Chinese Journal of Chemistry · doi:10.1002/cjoc.201800552 · Cited by 13

Targeting STAT3 anti-apoptosis pathways with organic and hybrid organic–inorganic inhibitors

Minus, M. B., Wang, H., Munoz, J. O., Stevens, A. M., Mangubat-Medina, A. E., Krueger, M., Liu, W., Kasembeli, M. M., Cooper, J. C., Kolosov, M. I., et al. (2020) · Organic & Biomolecular Chemistry · doi:10.1039/c9ob02682g · Cited by 13

The Discovery of Cryptic Pockets Increases the Druggability of “Undruggable” Proteins

Mou, M., Yang, W., Huang, G., Yang, X., Zhang, X. L., Kandegama, W., Ashby, C. R., Hao, G., & Gao, Y. (2025) · Medicinal Research Reviews · doi:10.1002/med.70001 · Cited by 14

Single-round evolution of RNA aptamers with GRAPE-LM

Zhang, J., Ju, Z., Tang, S., Liu, C., Cai, Y., Zeng, H., Meng, X., Liu, B., Zhang, Y., & Wang, Y. (2026) · Nature Biotechnology · doi:10.1038/s41587-026-03007-5 · Cited by 12

Chemical Proteomics with Novel Fully Functionalized Fragments and Stringent Target Prioritization Identifies the Glutathione-Dependent Isomerase GSTZ1 as a Lung Cancer Target

Liao, Y., Chan, S. C., Welsh, E. A., Fang, B., Sun, L., Schönbrunn, E., Koomen, J. M., Duckett, D. R., Haura, E. B., Monastyrskyi, A., et al. (2023) · ACS Chemical Biology · doi:10.1021/acschembio.2c00587 · Cited by 12

Lipid Metabolic Reprogramming in Embryonal Neoplasms with MYCN Amplification

Talapatra, J., & Reddy, M. M. (2023) · Cancers · doi:10.3390/cancers15072144 · Cited by 12

Targeting leucine-rich PPR motif-containing protein/LRPPRC by 5,7,4′-trimethoxyflavone suppresses esophageal squamous cell carcinoma progression

Liu, H., Zhou, Y., Fredimoses, M., Niu, P., Ge, Y., Wu, R. J., Liu, T., Li, P., Shi, Y., Shi, Y., et al. (2024) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2024.131966 · Cited by 12

Untangling the Role of MYC in Sarcomas and Its Potential as a Promising Therapeutic Target

Sias, F., Zoroddu, S., Migheli, R., & Bagella, L. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26051973 · Cited by 14

The Druggable Transcriptome Project: From Chemical Probes to Precision Medicines

Disney, M. D. (2025) · Biochemistry · doi:10.1021/acs.biochem.5c00006 · Cited by 11

Advancing target validation with PROTAC technology

Spitz, M. L., Kashkush, A., & Benhamou, R. I. (2025) · Expert Opinion on Drug Discovery · doi:10.1080/17460441.2025.2490248 · Cited by 12

FOXA1-dependent NSUN2 facilitates the advancement of prostate cancer by preserving TRIM28 mRNA stability in a m5C-dependent manner

Wang, Z., Abudurexiti, M., Zhu, W., Li, T., Xu, H., Wan, F., & Ye, D. (2025) · npj Precision Oncology · doi:10.1038/s41698-025-00904-x · Cited by 15

Optimization of the Linker Domain in a Dimeric Compound that Degrades an r(CUG) Repeat Expansion in Cells

Benhamou, R. I., Abe, M., Choudhary, S., Meyer, S. M., Angelbello, A. J., & Disney, M. D. (2020) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.0c00558 · Cited by 12

Control of Intracellular Molecular Networks Using Algebraic Methods

Vieira, L. S., Laubenbacher, R., & Murrugarra, D. (2019) · Bulletin of Mathematical Biology · doi:10.1007/s11538-019-00679-w · Cited by 11

Brachyury: Strategies for Drugging an Intractable Cancer Therapeutic Target

Robinson, H., McFarlane, R. J., & Wakeman, J. A. (2020) · Trends in cancer · doi:10.1016/j.trecan.2020.01.014 · Cited by 12

Loss of MYSM1 inhibits the oncogenic activity of cMYC in B cell lymphoma

Lin, Y. H., Wang, H., Fiore, A., Förster, M., Tung, L. T., Belle, J. I., Robert, F., Pelletier, J., Langlais, D., & Nijnik, A. (2021) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.16554 · Cited by 12

Sulfinyl Aziridines as Stereoselective Covalent Destabilizing Degraders of the Oncogenic Transcription Factor MYC

Rosen, H. T., Li, K., Stieger, C. E., Li, E. L., Currier, B., Brittain, S. M., Garcia, F. J., Beard, D. C., Jones, M. D., Haenni‐Holzinger, S., et al. (2025) · Angewandte Chemie International Edition · doi:10.1002/anie.202508518 · Cited by 15

Approach in Improving Potency and Selectivity of Kinase Inhibitors: Allosteric Kinase Inhibitors

Wei, S., Zhao, T., Wang, J., & Zhai, X. (2020) · Mini-Reviews in Medicinal Chemistry · doi:10.2174/1389557521666201222144355 · Cited by 12

Inhibition of deubiquitinase USP28 attenuates cyst growth in autosomal dominant polycystic kidney disease

Ren, Y., Zhu, X., Fu, K., Zhang, H., Zhao, W., Yang, L., Fang, Q., Wang, J., Chen, Y., & Guo, D. M. (2022) · Biochemical Pharmacology · doi:10.1016/j.bcp.2022.115355 · Cited by 11

Taking Aim at the Undruggable

Coleman, N., & Rodon, J. A. (2021) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbk_325885 · Cited by 59

Targeting the “undruggable” cancer driver genes: Ras, myc, and tp53

WU, X., Pan, D., Tang, S., & Shen, Y. (2023) · Biocell · doi:10.32604/biocell.2023.028790 · Cited by 4

Targeting “undruggable” cancer proteins: pharmacological challenges and emerging strategies

Coelho‐Silva, J. L., Parducci, N. S., Carvalho, M. F. L., Vahedian, V., Lima, K., de Almeida, B. O., & Machado‐Neto, J. A. (2026) · Translational Cancer Research · doi:10.21037/tcr-2025-1-2830 · Cited by 2

AJS-2 Unlocking undraggable targets: from mission impossible to mission achievable

Spreafico, A. (2025) · Annals of Oncology · doi:10.1016/j.annonc.2025.08.011

Drugging Undruggable Molecular Cancer Targets

Lazo, J. S., & Sharlow, E. R. (2015) · The Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev-pharmtox-010715-103440 · Cited by 234